John Ragard
Net worth: 37 591 $ as of 31/08/2026
Net worth: 37 591 $ as of 31/08/2026
John Ragard formerly worked at Aspira Women's Health, Inc., as Director from 2024 to 2025 and Friess Associates LLC, as Research Team Leader from 1993 to 2014.
Mr. Ragard received his undergraduate degree from The Wharton School of the University of Pennsylvania.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 04/06/2025 | 1,34,734 ( 0.29% ) | 37 591 $ | 31/08/2026 |
| Companies | Position | End |
|---|---|---|
| ASPIRA WOMEN'S HEALTH INC. | Director/Board Member | 04/06/2025 |
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Portfolio Manager-Equities | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 3 |
|---|---|
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Finance |
Aspira Women's Health, Inc.
Aspira Women's Health, Inc. BiotechnologyHealth Technology Develops and manufactures diagnostic test kits | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions